Company: Mitsubishi Tanabe Pharma Corporation
Drug Type: Small Molecule
Conditions: ALS, stroke
Mechanism Type: Anitoxidant
Mechanism: Edaravone is a free radical scavenger, which functions as an antioxidant by neutralizing peroxyl radicals and peroxynitrite. In mouse models of ALS, edaravone reduced motor neuron loss and functional decline. The drug is thought to help protect motor neurons in ALS by reducing oxidative stress.
U.S. Status for ALS: FDA Approved
 Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Abe, K et al. Lancet Neurol. 2017 May 15. pii: S1474-4422(17)30115-1.
 Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Abe, K et al. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec;15(7-8):610-7.
Last updated June 9th, 2017